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Abstract
Objective To develop and assess a short-duration JPRESS protocol for detection of overlapping metabolite biomarkers and 
its application to paediatric brain tumours at 3 Tesla.
Materials and methods The short-duration protocol (6 min) was optimised and compared for spectral quality to a high-
resolution (38 min) JPRESS protocol in a phantom and five healthy volunteers. The 6-min JPRESS was acquired from four 
paediatric brain tumours and compared with short-TE PRESS.
Results Metabolite identification between the 6- and 38-min protocols was comparable in phantom and volunteer data. For 
metabolites with Cramer–Rao lower bounds > 50%, interpretation of JPRESS increased confidence in assignment of lactate, 
myo-Inositol and scyllo-Inositol. JPRESS also showed promise for the detection of glycine and taurine in paediatric brain 
tumours when compared to short-TE MRS.
Conclusion A 6-min JPRESS protocol is well tolerated in paediatric brain tumour patients. Visual inspection of a 6-min 
JPRESS spectrum enables identification of a range of metabolite biomarkers of clinical interest.
Keywords Magnetic resonance spectroscopy · Metabolism · Brain neoplasms
Introduction
Metabolic reprogramming is an emerging hallmark of can-
cer [1]. Magnetic resonance spectroscopy (MRS) provides a 
convenient non-invasive means to investigate the metabolic 
composition of cancer. A wide range of metabolic changes 
have been identified in cohort studies of brain tumours [2, 
3]; however, unambiguous detection of some overlapping 
J-coupled metabolites in a single spectrum has been lim-
ited. Clinical applications of MRS have, therefore, typically 
focused on N-acetyl aspartate (NAA), lipids, creatine (Cr) 
and choline (Cho), which can be identified at short and long 
TE, and lactate (Lac), which can be distinguished from lipids 
and macromolecules at long TE.
In addition to the above, there is growing evidence that 
glutamate (Glu) [3, 4], glutamine (Gln) [5], glycine (Gly) 
[3, 6, 7], myo-Inositol (mI) [3, 8–10], scyllo-Inositol (Scy) 
[4] and taurine (Tau) [2, 9–11] are altered in paediatric brain 
tumours. Therefore, these metabolites may provide new 
markers of diagnosis, prognosis and identification of high-
risk patients, which may allow for better treatment stratifi-
cation and more effective disease management. However, 
identification of these metabolites is hindered by small peak 
intensities and spectral overlap leading to reduced repro-
ducibility [12] and increased Cramer–Rao lower bounds 
(CRLB) [13]. Various methods have been proposed for the 
detection of Glu, Gln, Gly, mI and Tau. These methods range 
in complexity from simply using an optimised TE [14–16] 
to more complex acquisition schemes such as TE averaging 
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[17] and quantum filters [18–20]. However, these meth-
ods are typically optimised for the detection of a specific 
metabolite and can sacrifice information from other relevant 
metabolite biomarkers. As use of all quantified metabolite 
data can improve the accuracy of tumour classification [21], 
acquisition methods that identify as many metabolites as 
possible are, therefore, preferred.
Commonly used in  vitro, J-resolved spectroscopy 
(JPRESS) [22, 23] has previously shown promise in brain 
tumours [24]. JPRESS is acquired by collecting PRESS 
spectra at multiple echo times, retaining the chemical shift 
information typical of conventional one-dimensional spec-
troscopy in F2, the x-dimension, and indirectly encoding the 
scalar coupling information for each metabolite in F1, the 
y-dimension. This spreads coupled metabolite resonances in 
two dimensions, disambiguating the identification of metab-
olites using the known chemical shift and scalar coupling 
constants for each metabolite based on their position in the 
spectrum [25].
One of the key challenges to implementing JPRESS in 
clinical practice is the associated long acquisition times. 
Children are often unable to tolerate long scanning sessions, 
making scan duration, particularly, pertinent in this setting. 
The aim of this study was to propose and test a short-dura-
tion JPRESS protocol, and evaluate its ability to detect and 
discriminate between overlapping metabolites of interest in 
paediatric brain tumours.
Materials and methods
The study was approved by the East Midlands—Derby 
Research Ethics Committee (REC 04/MRE04/41) operat-
ing under the rules of Declaration of Helsinki 1975 (and 
as revised in 1983), and informed consent was obtained 
from all volunteers and patients. The acquisition protocol 
was optimised using a combination of simulated, phan-
tom and volunteer data to determine the optimal spacing 
between TEs (ΔTE), number of TE steps acquired (NTE) 
and the number of averages (NSA) acquired per TE (NSA/
TE). A high-resolution 38.4-min JPRESS protocol was used 
for comparison to assess the reduction in spectral quality 
(Table 1).
Experimental
Simulations
JPRESS spectra of common brain metabolites [25] were sim-
ulated using VESPA [26]. 1D MRS of each metabolite was 
simulated using the VESPA pulse sequence option ‘PRESS 
Ideal’ at a range of echo times from 35 ms to 675 ms. A 
fixed TE1 (20 ms) was used with TE2 varied as required 
for each simulated TE. The standard PRESS sequence was 
repeated for each TE and the 1D MRS was combined with 
JPRESS datasets with ΔTEs of 5, 10, 15 and 20 ms. The 
JPRESS spectra were then visually assessed to determine 
the optimal TE spacing. The PRESS Ideal pulse sequence 
assumes ideal hard RF pulses which flip all spins during an 
infinitely short time with the same phase and angle. Experi-
mental acquisitions may be subject to signal cancellation due 
to phase variation and chemical shift displacement artefact 
for coupled spins such as lactate. In particular, the limited 
RF pulse bandwidth leads to spatially dependent evolution 
of J-coupling and consequently, additional artefact peaks 
at J = 0 Hz due to J-refocusing [27]. In general, however, 
the simulated JPRESS serves as a good approximation of 
metabolite peak patterns.
The 2D JPRESS spectra were further used as a reference 
library to aid metabolite identification and are presented 
in Online Resource 1; however, the spectrum for NAAG, 
which is typical of low abundance, does not include its asso-
ciated coupled resonances. Each metabolite spectrum was 
displayed with 40 contour lines up to a level of 50% of the 
maximum signal intensity for that metabolite and no mini-
mum threshold.
Phantom
MRS was acquired using a Philips Achieva 3T scan-
ner (Philips Healthcare, Best, Netherlands). JPRESS was 
acquired as a TE series and TE1 was fixed to 20 ms for 
experimentally acquired data. All averages for a given TE 
were acquired before acquiring data for the next linear TE, 
with the Philips function to mitigate the frequency drift 
applied.
Table 1  Acquisition protocols 
in phantom and volunteer 
for JPRESS protocol and 
processing development
All data were acquired with one dummy scan per TE and a water-unsuppressed spectrum collected with 
NSA 1 per TE
TR (ms) Starting 
TE (ms)
NSA/TE TE 
spacing 
(ms)
#TEs Maxi-
mum TE 
(ms)
Acquisition 
time (min)
Volunteers scanned
Protocol 1 2000 36 8 5 128 676 38.4 0 (2 Phantoms)
Protocol 2 2000 36 16 10 64 186 38.4 1
Protocol 3 2000 36 8 15 18 291 6 4 (2 Phantoms)
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Phantom data were acquired from two phantoms. A 
“braino” phantom (GE Medical Systems, Milwaukee, WI, 
USA) of common brain metabolites at physiological lev-
els containing 12.5 mM NAA, 12.5 mM Glu, 10 mM Cr, 
7.5 mM, mI, 5 mM Lac and 3 mM Cho was scanned. The 
second phantom contained 5 mM Glu, 5 mM Gln, 5 mM 
Gly and 5 mM mI to assess the resolution of key overlapping 
metabolites under experimental conditions.
1 g of sodium azide was added to each phantom as a bio-
cide to prevent the growth of bacterial organisms. The phan-
toms were pH adjusted to 7.2 and 0.5 mM and gadopentetate 
dimeglumine  (Magnevist®, Bayer HealthCare Pharmaceu-
ticals, Berlin, Germany) was added to each phantom as a 
relaxation agent to shorten relaxation times to the physi-
ological range.
Volunteer
Data were obtained from five healthy adults (three male and 
two female) with a mean age of 25 ± 2 years for the volunteer 
data. MRS of parietal grey matter was acquired from cubic 
voxels of size 30 × 30 × 30 mm3. The acquisition protocols 
for the phantom and volunteer data are presented in Table 1. 
Protocol 2 was assumed to be the gold standard for metabo-
lite detection due to its greater number of NSA/TE and the 
long echo train length. The spectral quality of the other pro-
tocols was assessed with reference to Protocol 2.
Protocol development
TE spacing
The spectral width of F1 is set by 1/ΔTE. Phantom data 
acquired with ΔTE = 5 ms (Protocol 1) were spliced to 
generate additional subsets with ΔTE of 10 ms, 15 ms and 
20 ms with the same NSA/TE and range of TEs.
NSA/TE
Volunteer data acquired with 8 NSA/TE (Protocol 3) and 16 
NSA/TE (Protocol 2) were acquired. The two spectra were 
compared to determine if the major resonances of Glu, Gln, 
and mI could be identified with fewer NSA/TE.
Number of TEs
Phantom and volunteer data with final TEs of 290 ms (Pro-
tocol 3) and 665 ms (Protocols 1 and 2) were compared to 
assess the effect that truncating the number of TEs acquired 
had on spectral resolution.
Clinical JPRESS of paediatric brain tumours
Four patients with paediatric brain tumours were inves-
tigated (Table 2). The optimised JPRESS protocol was 
acquired following conventional imaging.
JPRESS was acquired from cubic voxels of size 
30 × 30 × 30  mm3 for all the cases with TR = 2000  ms, 
 TEmin = 42 ms, NTE = 18, ΔTE = 15 ms and NSA/TE = 8. 
The total acquisition time was 6 min. PRESS with an echo 
time of 35 ms, TR of 2000 ms and 128 NSA was also 
acquired from the cases with medulloblastoma and diffuse 
intrinsic pontine glioma.
Data processing and analysis
The data were processed in two steps. First, the 1D MRS 
of each acquired TE was extracted and analysed with TAR-
QUIN v4.3.8 using the 1H Brain basis set [28]. TARQUIN 
estimates of the water peak position, ref, in the water-sup-
pressed spectra and CRLBs were recorded.
The full multi-TE dataset for each experiment was then 
transferred to a personal computer and processed using 
software written in-house in Python (v 2.7.3) to produce 
the 2D JPRESS spectra. The water component of the free 
induction decays was removed using Hankel singular value 
decomposition and the baseline was corrected for any dis-
placement to reduce interference. Baseline displacement 
correction was performed by taking the average value of 
a region of the spectrum containing only noise and no sig-
nal, and subsequently subtracting this value from the spec-
trum. Estimates of the water peak position, water_ref, in the 
water-suppressed spectra, were collected for each TE from 
the TARQUIN result file. Small frequency drifts between 
TEs caused broader resonances in the JPRESS F2 dimen-
sion. The water peak was, therefore, used as a chemical shift 
reference and was aligned to 4.65 ppm for all spectra in a 
dataset. Peak alignment was performed by multiplying each 
point, k, of the corresponding FID by exp(− 2πi × ref × k×-
(128⁄2000)), where ref = 4.65 ppm—water_ref, 128 MHz is 
the central 1H NMR frequency and 2000 Hz is the sampling 
frequency [29]. TARQUIN fits to NAA, Cho and Cr sin-
glets which were used to simulate spectra at TE > 297 ms to 
Table 2  Patient details of paediatric brain tumour patients studied 
with JPRESS
Age (years) Sex Tumour type
9.8 Male Medulloblastoma
8.2 Male Pilocytic astrocytoma
6.5 Female Optic pathway glioma
10.6 Male Diffuse intrinsic pon-
tine glioma (DIPG)
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reduce truncation artefacts caused by undersampling. Simu-
lated spectra were appended to the dataset with a relaxation 
penalty of exp(− TE/T2) [30], applied to successive echo 
times and a T2 of 200 ms assumed for all metabolites [31]. 
Using this method, the dataset was extended from 18 TEs 
(297 ms) to 30 TEs (477 ms) improving spectral resolution 
(Fig. 1).
The 2D Fourier-transformed JPRESS matrix was dis-
played as a contour plot in magnitude mode. Lower and 
upper bounds were used with thresholds adjusted to ensure 
spectra were clean and free of noise where possible. In 
each case, the thresholds were examined to determine if the 
metabolites could be identified in a more noisy spectrum. 
Spectral quality was determined through visual inspection of 
the display for artefacts. The thresholds of the display were 
further optimised manually to ensure that all desired peaks 
were present and fully resolved. The full data processing 
pipeline is shown in Fig. 2.
CRLBs were used to assess confidence in the presence of 
metabolites in short-TE PRESS.
Results
Protocol development and optimisation
The clinical JPRESS protocol was optimised for short acqui-
sition times by optimising the parameter settings of ΔTE, 
NTE and NSA/TE. The ability to detect key metabolites 
using short-duration 6-min JPRESS was compared with 
a 38.4-min JPRESS protocol, with the 38.4-min protocol 
assumed to be the gold standard for metabolite detection in 
this study.
Phantom
Figure 3 shows short-TE MRS and JPRESS acquired in a 
braino phantom (Fig. 3a–c) and a phantom containing equal 
quantities of Glu, Gln, Gly and mI (Fig. 3d–f). The position 
of JPRESS resonance peaks can be described by their J-cou-
pling (Hz) values and chemical shift (ppm) positions on the 
F1 and F2 axes, respectively. The Glu resonances with the 
greatest signal intensity are located at F2/F1 = 2.4 ppm/0 Hz 
and 2.35 ppm/− 7 Hz. mI presents as a complex arrangement 
of peaks between 3.5 and 3.6 ppm with characteristic reso-
nances off the F1 = 0 Hz axis at F2/F1 = 3.50 ppm/− 10 Hz, 
3.50 ppm/8 Hz and 3.60 ppm/5 Hz. The Gln resonance with 
Fig. 1  Representative examples 
of a acquired TE = 297-ms 
volunteer MRS from JPRESS 
acquisition and simulated 
TE = 312-ms MRS based 
on TARQUIN singlet fits to 
acquired TE = 297-ms MRS 
data. Simulated MRS was 
used to extend the JPRESS 
dataset. The F1 linewidths of 
b non-extended JPRESS were 
larger than those of c extended 
JPRESS for macromolecular 
resonances (0.5–1.5 ppm) 
and for coupled metabolites 
(2–3 ppm and 3.2–3.9 ppm)
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the highest signal intensity is located at 2.40 ppm/− 7 Hz 
and Gly presents as a single resonance at 3.55 ppm/0 Hz.
A 38.4-min-long JPRESS protocol (Protocol 1) was com-
pared with a shortened 6-min JPRESS protocol (Protocol 3). 
In both phantoms, all metabolite resonances fell within the 
F1 spectral range of ± 33 Hz and were visible using both pro-
tocols. Simulated JPRESS spectra of common brain metabo-
lites are presented in Online Resource 1, and all metabolite 
resonances simulated also fall within this range, which cor-
responds to a ΔTE of 15 ms.
Improved resolution in the F1 dimension was found in 
the 38.4-min protocol (Fig. 3b) with the tails of the NAA, 
Cr and Cho singlets longer in the shorter 6-min protocol 
(Fig. 3c). There was no observable difference in resolution 
of the F2 dimension between the two protocols.
The main Glu and Gln resonances were resolved in both 
protocols. The Gly resonance at F2/F1 = 3.54 ppm/0 Hz was 
indistinct from mI; however, mI could be detected from its 
off − 0 Hz resonances.
Volunteer
Figure 4 compares a 38.4-min JPRESS protocol (Fig. 4b) 
with a representative short 6-min protocol (Fig. 4d), and 
mI, Glu and Gln were identified by their characteristic 
resonance patterns in both the short and longer protocols; 
however, improved resolution of Glu and Gln was found in 
phantom data when compared to in vivo data. The 35-ms 
PRESS MRS (Fig. 4c) was unable to detect Gln, Tau or 
Fig. 2  Optimised acquisition 
protocol and processing pipeline 
for JPRESS of paediatric brain 
tumours
 Magnetic Resonance Materials in Physics, Biology and Medicine
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Gly; however, the corresponding short 6-min protocol dis-
criminated Gln.
JPRESS of paediatric brain tumours
Figure  5 shows the JPRESS spectrum and a short-TE 
35-ms PRESS spectrum acquired in the same scan-
ning session from a medulloblastoma prior to treat-
ment. The JPRESS resonance at F2/F1 = 3.54 ppm/0 Hz 
is most consistent with Gly, with no mI cross-peaks 
observed. The corresponding short-TE MRS reso-
nance was assigned to Gly (CRLB = 12.9%) with no 
mI detected. Resonances were also present at F2/
F1 = 3.40 ppm/0 Hz and 3.34 ppm/− 7 Hz. While the 
location of these resonances is most consistent with 
Tau, the F2/F1 = 3.40 ppm, 0 Hz resonance was twice 
as large as that at 3.34 ppm/− 7 Hz. The corresponding 
resonances of the simulated Tau JPRESS were of equal 
intensity. There is, therefore, an unassigned resonance at 
F2/F1 = 3.40 ppm, 0 Hz with no obvious associated reso-
nances. The short-TE CRLB for Tau was 12.8%; however, 
there was a small residual peak in this region. The lac-
tate doublet (short-TE CRLB = 112%) and lipid peak at 
1.3 ppm (short-TE CRLB = 124%) were well separated in 
Fig. 3  a 35-ms PRESS, b 38.4-min JPRESS (Protocol 1) and c 6-min 
JPRESS of the braino phantom (Protocol 3). d 35-ms PRESS, e 38.4-
min JPRESS (Protocol 1) and f 6-min JPRESS (Protocol 3) of a phan-
tom containing 5 mM Glu, 5 mM Gln, 5 mM Gly and 5 mM mI. For 
comparison of spectral quality, b and e show only the F1 spectral 
range from − 33 Hz to + 33 Hz, with the whole spectrum inset top 
right and dashed lines showing F1 = ± 33 Hz
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JPRESS. Glu (short-TE CRLB = 54.2%) and Gln (short-
TE CRLB = 94.2%) were not detected in the JPRESS 
spectrum.
Figure 6 shows the JPRESS spectrum and the extracted 
short-TE (42 ms) MRS of a pilocytic astrocytoma (SNR 
12.8). The resonances between 3.5 and 3.6  ppm were 
assigned by TARQUIN to Gly (short-TE CRLB = 41.7%) 
and mI (short-TE CRLB = 53.5%) with the peaks at 
3.55  ppm being of equal intensity. The intensities of 
the JPRESS resonances at F2/F1 = 3.54  ppm/0  Hz and 
3.54 ppm/− 11 Hz are approximately equal, which is con-
sistent with a combination of mI and Gly. Scy was also pre-
sent in the JPRESS spectrum at 3.34 ppm/0 Hz and in the 
short-TE analysis (CRLB = 118%). Glu (CRLB = 67.1%) and 
Gln (not detected in short-TE MRS) were not detected in the 
JPRESS spectrum.
The JPRESS and corresponding short-TE (35 ms) MRS 
of an optic pathway glioma (OPG) are shown in Fig. 7. 
The short-TE assignments to the peaks at F1 = 0  Hz, 
F2 = 3.50, 3.6 and 3.8 ppm were to mI, mI and Glth with 
short-TE CRLBS of 67.3% for mI and 67.1% for Glth. 
The JPRESS shows the characteristic mI peak at F1/
F2 = 3.50 ppm/− 10 Hz and also shows the splitting of the 
Lac doublet at 1.3 ppm. No Lac was detected in the short-TE 
MRS analysis. Glu (CRLB = 106%) and Gln (CRLB = 164%) 
were not detected in the JPRESS spectrum.
The JPRESS and short-TE PRESS spectra (SNR = 12.2) 
of a DIPG post-radiotherapy are shown in Fig.  8. The 
resonances between − 20 Hz and 10 Hz at approximately 
3.54 ppm are most consistent with mI. The vast major-
ity of this region in the short-TE PRESS was assigned 
to mI (CRLB = 13.2%) with a small amount of Gly 
(CRLB = 112%) present. Glu (CRLB = 134%) and Gln 
(CRLB = 110%) were not detected in the JPRESS spectrum. 
Since mI is a complex multiplet, a large FWHM leads to 
individual peaks merging and, therefore, a different over-
all lineshape being formed when compared with the cases 
where the FWHM is small and the individual peaks are bet-
ter resolved. This effect is seen in the DIPG spectrum where 
the FWHM is 8 Hz (Fig. 8) compared to the OPG spectrum 
where the FWHM is 4 Hz (Fig. 7).
Discussion
This study presents a 6-min clinical protocol for JPRESS 
developed for visual detection of key metabolites found in 
paediatric brain tumours and its application to a series of 
cases. The protocol was optimised using a braino phantom 
and volunteer data with the short-duration protocol’s effi-
cacy assessed by comparing with a longer protocol which 
was taken as the reference standard.
Fig. 4  a 35-ms PRESS and b 38.4-min JPRESS (Protocol 2) of 
healthy grey matter in a female volunteer. c 35-ms PRESS and d 
6-min JPRESS (Protocol 3) of a healthy grey matter in a male volun-
teer. For comparison of spectral quality, b shows only the F1 spectral 
range from − 33 Hz to + 33 Hz, with the whole spectrum inset top 
right and dashed lines showing F1 = ± 33 Hz
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The main metabolites of interest in this study were Glu, 
Gln, Gly, mI, Scy and Tau due to their roles in cancer 
metabolism. Metabolite identification was assessed in 
phantom and volunteer JPRESS spectra acquired with 8 
NSA/TE and 16 NSA/TE. Glu, Gln and mI could all be 
identified in the 8 NSA/TE volunteer spectra and these 
were selected to reduce the scan duration. The absence of 
Gly, Scy and Tau was expected in volunteers due to their 
relative low abundance in healthy brain [25] but they are 
of sufficiently high concentration in some brain tumours 
that the same NSA/TE should be appropriate for these 
metabolites [2]. Further reduction of the protocol duration 
was obtained by considering the final TE acquired. Due to 
their relatively small peak intensities, a final TE of 297 ms 
was sufficient for strongly coupled resonances to be indis-
tinguishable from the noise following T2 relaxation decay, 
but for singlets, approximately 20% of the metabolite sig-
nal remains assuming typical T2 relaxation times [29].
Not acquiring MRS with a TE greater than 297  ms 
reduced acquisition time and did not cause major artefacts 
in the JPRESS spectral when the singlet decay at longer echo 
times was simulated. The ΔTE increment was increased to 
15 ms for a J-resolved bandwidth of 67 Hz, which was con-
sidered to be the bandwidth required to observe all coupled 
resonances of common metabolites [25]. While the ∆TE 
increment used here is sufficient for metabolite detection, 
smaller ∆TE increments are also used for JPRESS applica-
tions [22] as these can help avoid artefacts caused by signal 
folding due to insufficient water suppression or no or non-
optimal apodisation.
In the four paediatric brain tumour cases, metabolites of 
interest were confirmed or excluded based on the JPRESS 
spectrum compared with the short-TE MRS. In the medul-
loblastoma case, Gly and Tau were identified with peak posi-
tions and J-coupled resonances consistent with metabolite 
simulations. The short-TE analysis was consistent with the 
interpretation of the JPRESS spectrum, with a small residual 
peak between 3.30 and 3.40 ppm. Based on the JPRESS 
Fig. 5  a JPRESS spectrum of medulloblastoma, b 35-ms PRESS of 
medulloblastoma collected in the same session. TARQUIN residual 
and fits (FWHM = 7 Hz) for Gly and Tau included
Fig. 6  a JPRESS spectrum of pilocytic astrocytoma, b 1D MRS 
extracted from the pilocytic astrocytoma JPRESS dataset with a 
TE of 42-ms. TARQUIN fits (FWHM = 7  Hz) for mI, Gly and Scy 
included
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appearance, this could be due to an unassigned singlet peak. 
The medulloblastoma JPRESS was consistent with ex vivo 
HR-MAS analysis [32]. Interpretation of JPRESS, with 
the aid of simulated data, also corroborated the TARQUIN 
assignments of Gly, mI and Scy in the short-TE MRS pilo-
cytic astrocytoma patient case. TARQUIN analysis of the 
short-TE DIPG MRS indicated that mI was the predomi-
nant metabolite at 3.50 ppm, which was consistent with the 
JPRESS spectrum. In the optic pathway glioma patient, the 
JPRESS indicated that Glth, mI and Lac were present in 
the voxel, whilst TARQUIN’s assignments in the short-TE 
PRESS had CRLB > 50% for Glth and mI and Lac was not 
fitted. The discrimination of these metabolites of interest has 
clinical relevance for both diagnosis and prognosis. DIPG 
and OPG patients rarely have biopsies and, therefore, imag-
ing plays a vital role in their tumour diagnosis. The dis-
crimination of Gly and mI is of particular importance as Gly 
has been found to be a survival marker in paediatric brain 
tumours [33], while Scy is also a marker of survival [5]. 
The confidence in the assignment of these metabolites is, 
therefore, of value and JPRESS can be used in a short scan 
time to achieve this, with the features seen in the low-grade 
optic pathway glioma and pilocytic astrocytomas reflecting 
those commonly identified ex vivo [34].
One of the key advantages of JPRESS over short-TE MRS 
is that visual inspection increases confidence in metabolite 
assignment. CRLBs are the standard method of assessing 
confidence in 1D MRS metabolite assignments. While for 
reliable metabolite quantification, the consensus CRLB 
threshold is 20%, there is consensus that metabolites can be 
detected with high confidence when CRLBs are less than 
50% [35]. However, in the short-TE analysis of patients in 
this study, several key metabolites of clinical interest had 
CRLBs > 50% but were clearly present in the JPRESS spec-
trum. These included Lac in the medulloblastoma and OPG, 
mI in the PA and OPG and Scy in the PA, with Gly also hav-
ing a relatively high CRLB of 41.7% in the PA.
A range of methods are available for the detection of 
metabolite biomarkers of disease and prognosis, includ-
ing optimised TE 1D MRS and other spectral-editing 
Fig. 7  a JPRESS spectrum of optic pathway glioma (OPG), b 35-ms 
PRESS of OPG collected in the same session. TARQUIN residual 
and fits (FWHM = 4 Hz) for Lac, mI and Glth included
Fig. 8  a JPRESS spectrum of diffuse intrinsic pontine gliomas 
(DIPG), b 35-ms PRESS of DIPG collected in the same session. 
TARQUIN residual and fits (FWHM = 8 Hz) for mI and Gly included
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approaches. JPRESS was chosen ahead of these as 2D 
methods do not suppress or enhance metabolite reso-
nances, allowing a wide range of metabolites to be poten-
tially identified. JPRESS was also chosen ahead of 
L-COSY [36] as it is more readily available on clinical 
3 T MR systems without modification and has regulatory 
approval (CE-marking) on the scanner used in this study; 
however, the analysis itself is not CE-marked. JPRESS 
also offers the facility to extract the short- and long-TE 
1D MRS spectra that radiologists are already familiar 
with interpreting, aiding its translation into the clinical 
environment; however, these extracted spectra will have 
lower SNR than a typical 1D MRS acquisition. Further 
improvement of JPRESS could be conferred by optimis-
ing the apodisation function or by the use of a weighted 
averaging acquisition [37].
While the presented JPRESS protocol offers some clear 
advantages over conventional short-TE PRESS, there are a 
number of limitations to this study. First, with visual detec-
tion of key metabolite biomarkers being the aim of this 
study, no attempt was made to quantify metabolite concen-
trations. However, while quantification was not performed 
here, a recent study of short-duration JPRESS observed a 
test–retest reliability < 10% for NAA, Cho, Glth, Glu and 
mI [38]. 2D JPRESS can also be quantified using the desig-
nated quantification package ProFit [39], which could yield 
the same, or better results, as those achieved here by visual 
inspection. While ProFit was not used in this study, a com-
parison of the two approaches would be a logical extension 
to this work and will be examined in future work.
Second, a voxel of size 30 × 30 × 30 mm3 was used 
to ensure sufficient SNR. Though this voxel is large, this 
JPRESS protocol would be suitable for brain tumours which 
have not been resected, with metabolite-specific pulse 
sequences used to follow-up response to treatment for pre-
selected metabolites. Recent advances, such as the combina-
tion of JPRESS with fast echo-planar spectroscopic imaging 
approaches [40, 41], are likely to mitigate the partial volume 
problems associated with large voxels. These methods typi-
cally require the use of a research mode on clinical scanners, 
but should also be investigated.
Third, while both Glu and Gln could be identified in 
healthy volunteers, they were not detected in any of the four 
paediatric brain tumours investigated with JPRESS. This is 
likely due to the lower abundance of these metabolites in 
brain tumours compared with age-matched normal brain [3]. 
In the corresponding short-TE MRS, Glu and Gln consist-
ently had CRLBs > 50%; however, a greater NSA/TE might 
be better suited for the detection of these metabolites. While 
we did not thoroughly explore the effect of varying the NSA/
TE, we chose to acquire eight averages per TE to maximise 
SNR. Reducing the NSA/TE may be able to achieve similar 
spectral quality in a shorter timeframe, while scanning more 
TEs with a smaller NSA/TE could potentially be used to 
improve spectral quality.
Finally, while JPRESS has the potential to identify or 
confirm the presence of novel metabolite biomarkers, metab-
olite assignment can still be a non-trivial task. It is hoped 
that the simulated JPRESS spectra presented in Online 
Resource 1 will aid others in basic metabolite assignment. 
High-resolution experiments using ex vivo tissue could help 
to elucidate metabolite spectra further.
Conclusions
A 6-min JPRESS protocol was well tolerated in a paediat-
ric setting and was able to detect metabolite biomarkers of 
disease and prognosis in childhood brain tumours. Visual 
inspection of JPRESS confirmed the presence of metabolites 
with high CRLBs in short-TE MRS and would be suitable 
for use in patients with large tumours.
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